RPAM
BCAX

Rhenman & Partners Asset Management’s Bicara Therapeutics BCAX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Buy
+88,150
New +$1.97M 0.25% 86

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rhenman & Partners Asset Management's BCAX Position: Q2 2026 in Review

Rhenman & Partners Asset Management opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 88,150 shares worth $2.62M. The stake represents 0.25% of the portfolio and ranks #86 among its holdings.

172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Rhenman & Partners Asset Management held 88,150 shares of Bicara Therapeutics worth $2.62M as of Q2 2026.
  • Bicara Therapeutics was a new Rhenman & Partners Asset Management position in Q2 2026.
  • Bicara Therapeutics made up 0.25% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #86 holding.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.